Why quotes disappeared when the company stopped filing, what the Expert Market permits, and the one question worth asking your broker.
When a company's stock suddenly disappears from public quote services, it can be a jarring experience for investors. One day you see bids and asks, the next day, nothing. This often happens when a company stops filing its required reports with the Securities and Exchange Commission (SEC) or its alternative reporting standard, such as OTC Markets Group's Pink Basic Disclosure Guidelines.
The disappearance of public quotes is a direct consequence of SEC Rule 15c2-11, a critical regulation governing the publication of quotations for over-the-counter (OTC) securities. Understanding the changes to this rule, particularly those that became effective in September 2021, is essential for anyone holding shares in non-reporting or delinquent companies.
SEC Rule 15c2-11, originally adopted in 1971, was designed to prevent fraud and manipulation in the OTC market by requiring broker-dealers to have certain current information about an issuer before publishing a quotation for its securities. The rule aimed to ensure that investors had access to basic information about a company before making investment decisions.
Over the decades, the OTC market evolved significantly, with various platforms and disclosure standards emerging. However, a persistent issue remained: many companies trading OTC provided little to no current public information. This lack of transparency created fertile ground for scams and made it difficult for investors to conduct proper due diligence.
In 2020, the SEC adopted amendments to Rule 15c2-11, which became effective on September 28, 2021. These amendments fundamentally changed how broker-dealers could publish quotations for OTC securities. The core principle behind the updated rule is that public quotes should only be available for companies that make current information publicly available.
Specifically, the amended Rule 15c2-11 generally prohibits a broker-dealer from publishing a quotation for an OTC security unless the issuer of that security has made current financial and other material information publicly available. This information must be accessible through the SEC's EDGAR system, a foreign regulator's website, or an interdealer quotation system (like OTC Markets Group) that makes the information publicly available.
The most immediate and noticeable impact of the amended Rule 15c2-11 for many investors was the sudden cessation of public quotes for companies that were not current in their reporting. If a company failed to file its annual reports on Form 10-K or Form 10-Q, or if it did not meet the disclosure requirements of an alternative reporting standard, broker-dealers were generally prohibited from publishing bid and ask quotations for its stock.
Before the rule change, many broker-dealers relied on an exception that allowed them to publish unsolicited quotations, even for companies with little public information. This exception was largely eliminated by the 2021 amendments, tightening the reins on what could be publicly quoted.
When a company stops filing its required reports, it becomes a "non-reporting" company in the eyes of the SEC. This status triggers the application of the amended Rule 15c2-11's restrictions. Without current public information, the market makers - the broker-dealers who provide liquidity by quoting bid and ask prices - are no longer permitted to display these quotes on public platforms like OTC Link ATS (operated by OTC Markets Group).
The absence of public quotes means that the stock effectively becomes illiquid on public platforms. While shares may still exist and be owned, the ability to easily see a market price and execute trades through standard brokerage interfaces disappears. This situation can leave investors with what are colloquially known as trapped shares, where the ability to sell or even determine a fair value becomes significantly impaired.
The SEC recognized that there might still be a legitimate need for broker-dealers to facilitate transactions in securities of non-reporting companies, particularly for institutional investors or sophisticated parties who can conduct their own due diligence. To address this, the amendments to Rule 15c2-11 introduced the concept of the "Expert Market."
The Expert Market is a specific designation within the OTC market for securities that do not qualify for public quotation under the amended Rule 15c2-11. It allows broker-dealers to publish "unsolicited quotations" for these securities, but with a critical difference: these quotes are only available to "qualified" subscribers of the interdealer quotation system (e.g., OTC Link ATS). They are not publicly displayed to retail investors or the general public.
What does this mean in practice? If your stock moved to the Expert Market, it means:
The Expert Market is designed to be a venue for professional trading, not for broad public participation. Its existence acknowledges that some level of trading in these securities may be necessary for various reasons, such as resolving estates, unwinding positions, or facilitating transactions between sophisticated parties, without creating a public market that lacks adequate information.
For investors whose shares have moved to the Expert Market, the situation can be frustrating. The primary challenge is the lack of visible liquidity and the difficulty in executing trades. While the company's shares still exist and you still own them, the practical ability to sell them at a reasonable price can be severely hampered.
If you find yourself in this position, there is one crucial question you should ask your broker: "Can you facilitate an unsolicited customer order for my shares in the Expert Market?"
This question is important because it clarifies whether your broker has the capability and willingness to attempt to execute a trade for you in this limited venue. Not all brokers may be equipped or willing to do so, especially for smaller positions or less common securities. An "unsolicited customer order" means you are initiating the trade, not that your broker is soliciting you to buy or sell.
Even if your broker can facilitate such an order, be prepared for potential challenges:
It is also worth noting that some companies, after moving to the Expert Market, may eventually resume reporting and qualify for public quotation again. However, this is often a lengthy and uncertain process. Investors should monitor company announcements, if any, and check the company's status on platforms like OTC Markets Group for any updates on their reporting compliance.
Understanding these dynamics is crucial for investors in the OTC space. The shift to the Expert Market is a regulatory consequence of non-compliance, not a punitive action against investors, but its effects are certainly felt by shareholders. For more on how to identify potential reporting issues, consider reviewing resources on catalyst radar, which often includes monitoring for filing delinquencies.
The Expert Market is a direct outcome of the SEC's efforts to enhance transparency and protect investors in the OTC market by limiting public quotations to companies that provide current information. For investors, it underscores the importance of due diligence and understanding a company's reporting status before and during an investment. Always remember, this information is for educational purposes only and not investment advice.
All of this is verifiable from free public records. Confirm the current quotation tier on OTC Markets, then open the company on SEC EDGAR and look at the date of the most recent 10-K or 10-Q. A long gap, or a Form 15, is the pattern behind most Expert Market moves. Check the SEC list of trading suspensions for the symbol, and if the restriction may sit with your broker rather than the market, confirm the firm on FINRA BrokerCheck.
Our free Check My Stock tool runs those lookups for a single ticker and shows what the public record supports.
Each week: the micro and small-caps now showing dilution or paid-promotion signals, with the SEC filing behind every flag. No recommendations, no price targets.